- Mosapride
-
- $44.00 / 10mg
-
2026-04-16
- CAS:112885-41-3
- Min. Order:
- Purity: 99.85%
- Supply Ability: 10g
- Mosapride
-
- $15.00 / 1KG
-
2021-07-13
- CAS:112885-41-3
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Mosapride
-
- $15.00 / 1KG
-
2021-07-09
- CAS:112885-41-3
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | Mosapride Basic information |
| | Mosapride Chemical Properties |
| Melting point | 151-153°C | | Boiling point | 549.2±50.0 °C(Predicted) | | density | 1.272±0.06 g/cm3(Predicted) | | storage temp. | Keep in dark place,Sealed in dry,Room Temperature | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | 13.52±0.46(Predicted) | | form | Solid | | color | White to Off-White | | CAS DataBase Reference | 112885-41-3(CAS DataBase Reference) |
| | Mosapride Usage And Synthesis |
| Description | Mosapride citrate, a new gastroprokinetic benzamide was introduced in
Japan as Gasmotin for the relief of gastrointestinal symptoms in patients with
chronic gastritis, gastro-oesophageal reflux, dyspepsia and post-surgery use.
Mosapride is synthesized by final amidation between the corresponding benzoic
acid, itself obtained in 3 steps from methyl 4-acetamido salicylate, and the
appropriate 2-aminomethyl-morpholine. Mosapride is a 5-HT4 partial agonist
without notable activity for D2, 5-HT1 , 5-HT2, alpha-1 and alpha-2 receptors. In
dogs, mosapride was as potent as cisapride to stimulate antral and duodenal
motility. In most of species including man, mosapride undergoes extensive
cleavage to a N-debenzylated metabolite which retains partial 5-HT4 activity but
has potent 5-HT3 antagonist activity. | | Chemical Properties | White to Off-White Crystalline Solid | | Originator | Dainippon (Japan) | | Uses | A selective 5-HT4 receptor agonist. Gastroprokinetic. | | Uses | gastroprokinetic agent | | Definition | ChEBI: Mosapride is a racemate comprising equimolar amounts of (R)- and (S)-mosapride. It is a gastroprokinetic agent which acts on 5-hydroxytryptamine type 4 (5-HT4) receptors in the gastrointestinal plexus, consequently increasing the release of acetylcholine and hence enhancing gastrointestinal motility and gastric emptying. It has a role as a gastrointestinal drug and a serotonergic agonist. It contains a (R)-mosapride and a (S)-mosapride. | | Brand name | Gasmotin | | Hazard | A poison by ingestion. | | Safety Profile | A poison by ingestion.
When heated to decomposition it emits
toxic vapors of NOx, F-, and Cl-. | | Synthesis | The general procedure for the synthesis of 4-amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)morpholin-2-yl)methyl)benzamide from compound (CAS: 636582-70-2) was as follows: 12 mL (117%) of aqueous hydrochloric acid was added to a suspension of 1.3 g (2.5 mmol) of compound (VIII) and 3 mL of water. The resulting solution was stirred at 40 °C for 3 h. After cooling to 10 °C, 38 mL of a 4 M aqueous sodium hydroxide solution was added dropwise. The precipitated mosapride base (Formula IX) was filtered and washed twice with water to give 1.05 g (100%) of compound (IX). 1.01 g of compound (IX) obtained above was dissolved in 25 mL of 10% citric acid aqueous solution under stirring, heated to boiling, cooled to 0°C and filtered the precipitated product, washed twice with water to give 1.34 g (86%) of 4-amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)morpholin-2-yl)methyl)benzamide. Melting point: 110-113°C. | | References | [1] Patent: WO2003/106440, 2003, A2. Location in patent: Page 10 |
| | Mosapride Preparation Products And Raw materials |
|